Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prime MedicinePRME -1.92%25 3-Year EBITDA Growth Rate is 26.30% as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,137 Biotechnology companies, Prime Medicine ranks better than 62.27% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -99.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Prime Medicine was 26.30% per year. The lowest was -455.00% per year. And the median was -12.30% per year.
Prime Medicine (NAS:PRME) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Prime Medicine 3-Year EBITDA Growth Rate Related Terms
PRME vs EIKN, CRMD, STTK: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Prime Medicine's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Prime Medicine's 3-Year EBITDA Growth Rate falls into.
Prime Medicine 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 26.30% mean?
Prime Medicine (PRME) has a 3-Year EBITDA Growth Rate of 26.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prime Medicine and its competitors. According to the industry distribution chart, Prime Medicine ranks #429 out of 1137 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Prime Medicine's 3-Year EBITDA Growth Rate too high?
Prime Medicine's current 3-Year EBITDA Growth Rate is 26.30%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Prime Medicine's value of 26.30% is 77.7% above this industry median. Based on the distribution chart, Prime Medicine ranks #429 out of 1137 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's 3-Year EBITDA Growth Rate compare to EIKN and CRMD?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #429 out of 1137 companies for 3-Year EBITDA Growth Rate. This puts Prime Medicine in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.80. Prime Medicine's value of 26.30% is 77.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prime Medicine's current 3-Year EBITDA Growth Rate of 26.30% is 77.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prime Medicine and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current 3-Year EBITDA Growth Rate is 26.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current 3-Year EBITDA Growth Rate of 26.30%. The current 3-Year EBITDA Growth Rate is 26.30% and 77.7% above the Biotechnology industry median of 14.80. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Prime Medicine (PRME), the current 3-Year EBITDA Growth Rate is 26.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score
Get the complete analysis for PRME
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
